Insider Buying: iBio, Inc. (NYSE:IBIO) CFO Purchases $24,999.52 in Stock

iBio, Inc. (NYSE:IBIO) CFO Felipe Duran acquired 9,191 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were purchased at an average price of $2.72 per share, with a total value of $24,999.52. Following the completion of the transaction, the chief financial officer now owns 11,139 shares of the company’s stock, valued at $30,298.08. This trade represents a 471.82 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

iBio Trading Up 4.4 %

IBIO stock opened at $2.85 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.37 and a current ratio of 3.37. The company’s fifty day simple moving average is $2.51 and its 200 day simple moving average is $2.29. iBio, Inc. has a 12-month low of $1.02 and a 12-month high of $4.98.

iBio (NYSE:IBIO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.46). As a group, research analysts predict that iBio, Inc. will post -1.74 EPS for the current fiscal year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.